[1]邢岩,赵晋华.18F-氟脱氧葡萄糖PET及PET-CT早期诊断肿瘤复发[J].国际放射医学核医学杂志,2007,31(6):341-344.
 XING Yan,ZHAO Jin-hua.18F-fluorodeoxyglucose PET and PET-CT in early detection of cancer recurrent[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(6):341-344.
点击复制

18F-氟脱氧葡萄糖PET及PET-CT早期诊断肿瘤复发(/HTML)
分享到:

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
31
期数:
2007年第6期
页码:
341-344
栏目:
临床核医学
出版日期:
1900-01-01

文章信息/Info

Title:
18F-fluorodeoxyglucose PET and PET-CT in early detection of cancer recurrent
作者:
邢岩 赵晋华
200080 上海, 上海交通大学附属第一人民医院核医学科
Author(s):
XING Yan ZHAO Jin-hua
Department of Nuclear Medicine, Shanghai First People’s Hospital, Shanghai Jiaotong University, Shanghai 200080, China
关键词:
氟脱氧葡萄糖F18体层摄影术发射型计算机体层摄影术X线计算机肿瘤复发局部
Keywords:
Fluorodeoxyglucose FI8Tomographyemission-computedTomographyX-ray computedNeoplasm recurrentlocal
分类号:
R817.4
摘要:
早期探测肿瘤复发可以改善患者的预后,延长其生存期。18F-氟脱氧葡萄糖(18F-FDG)PET能在组织结构变化之前早期探测代谢变化,PET-CT中同机CT提供的融合图像能够对病灶进行精确定位,在早期诊断肿瘤复发方面显示功能与解剖信息互补的作用。除能准确诊断和确定肿瘤复发程度外,18F-FDGPET及PET-CT还能进一步影响患者的治疗。
Abstract:
Early detection of recurrent can improve prognosis and survival of patients with cancer. 18-fluorodeoxyglucose(18F-FDG) PET can detect metabolic changes before structural changes. The fused imaging provided by PET-CT can precisely localize the loci and demonstrate the complementary roles of functional and anatomic assessments in the diagnosis of cancer recurrence. In addition to the accurate diagnosis and definition of the whole extent of recurrent cancer, 18F-FDG PET and PET-CT can impact patients’ management.

参考文献/References:

1 Adam R, Vinet E. Regional treatment of metastasis:surgery of colorectal liver metastases. Ann Oncol,2004,15(suppl 4):iv103-iv106.
2 Israel O, Kuten A. Early detection of cancer recurrence:18F-FDG PET/CT can make a difference in diagnosis and patient care. J Nucl Med, 2007, 48(Suppl):28S-35S.
3 Schroder FH, Roobol MJ. Words of wisdom. Re:prostate-specific antigen(PSA)and PSA velocity for prostate cancer detection in men aged <50 years. Eur Urol, 2007, 52(3):922.
4 Flamen P, Hoekstra OS, Homans F, et al. Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer:the utility of positron emission tomography (PET). Eur J Cancer, 2001, 37(7):862-869.
5 Hung GU, Shiau YC, Tsai SC, et al. Value of 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent colorectal cancer. Anticancer Res, 2001, 21(2B):1375-1378.
6 Kalff V. Hicks RJ, Ware RE, et al. The clinical impact of 18F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer:a prospective study. J Nucl Med, 2002, 43(4):492-499.
7 Krestin GP, Steinbrich W, Friedmann G. Recurrent rectal cancer:diagnosis with MR imaging versus CT. Radiology, 1988, 168(2):307-311.
8 Huebner RH, Park KC, Shepherd JE, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med, 2000, 41(7):1177-1189.
9 Torizuka T, Nobezawa S, Kanno T, et al, Ovarian cancer recurrence:role for whole-body positron emission tomography using 2-[fluorine18]-fluoro-2-deoxy-D-glucose. Eur J Nucl Med Mol Imaging, 2002, 29(6):797-803.
10 Zimny M, Siggelkow W, Schroder W, et al. 2-[Fluorine-18]-fluoro-2eoxyglucose positron emission tomography in the diagnosis of recurrent ovarian cancer. Gynecol Oncol, 2001, 83(2):310-315.
11 Kostakoglu L, Agress H, Goldsmith J. Clinical role of FDG PET in evaluation of cancer patients. Radiographics, 2003, 23(2):315-340.
12 Bar-Shalom R, Yefremov N, Guralnik L, et al. Clinical performance of PET/CT in evaluation of cancer:additional value for diagnostic imaging and patient management. J Nucl Med, 2003, 44(8):1200-1209.
13 Isasi CR, Moadel R, Blaufox MD. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat, 2005, 90(2):105-112.
14 Radan L, Ben-Haim S, Bar-Shalom R, et al. The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer, 2006, 107(11):2545-2551.
15 Suarez M, Perez-Castejon MJ, Jimenez A, et al. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers. Q J Nucl Med, 2002, 46(2):113-121.
16 Aide N, Huchet V, Switsers O, et al. Influence of CA 15-3 blood level and doubling time on diagnostic performances of 18F-FDG PET in breast cancer patients with occult recurrence. Nucl Med Commun, 2007, 28(4):267-272.
17 Simcock B, Neesham D, Quinn M, et al. The impact of PET/CT in the management of recurrent ovarian cancer. Gynecol Oncol, 2006, 103(1):271-276.
18 Murakami M, Miyamoto T, Iida T, et al. Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer. Int J Gynecol Cancer, 2006, 16(Suppl 1):99-107.
19 Havrilesky LJ, Kulasingam SL, Matchar DB, et al. FDG-PET for management of cervical and ovarian cancer. Gynecol Oncol, 2005, 97(1):183-191.
20 Grigsby PW, Siegel BA, Dehdashti F, et al. Posttherapy surveillance monitoring of cervical cancer by FDG-PET. Int J Radiat Oncol Biol Phys, 2004, 55(4):907-913.
21 Lai CH, Huang KG, See LC, et al. Restaging of recurrent cervical cancer with dual-phase[18F]fluoro-2-deoxy-D-glucose positron emission tomography. Cancer, 2004, 100(3):544-552.
22 Lin CT, Yen TC, Chang TC, et al. Role of[18F] fluoro-2-deoxy-Dglucose positron emission tomography in re-recurrent cervical cancer. Int J Gynecol Cancer, 2006, 16(6):1994-2003.
23 Kim JH, Czernin J, Allen-Auerbach MS, et al. Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer, J Nucl Med, 2005, 46(4):587-595.
24 Votrubova J, Belohlavek O, Jaruskova M, et al. The role of FDG-PET/CT in the detection of recurrent colorectal cancer. Eur J Nucl Med Mol Imaging, 2006, 33(7):779-784.
25 Cohade C, Osman M, Leal J, et al. Direct comparison of 18F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med, 2003, 44(11):1797-1803.
26 Shen YY, Liang JA, Chen YK, et al. Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA)in Taiwan. Hepatogastroenterology, 2006, 53(69):348-350.
27 Pracchia LF, Chaves AR, Cerci JJ, et al. Metabolic test with fluorine18-fluorodeoxyglucose in staging and cetetion fo residual tumor or recurrence in Hodgkin lymphoma. Clinics, 2007, 62(2):121-126.
28 Panizo C, Perez-Salazar M, Bendandi M, et al. Positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual Hodgkin’s disease medlastinal masses. Leuk Lymphoma, 2004, 45(9):1829-1833.
29 Guay C, Lepine M, Verreault J, et al. Prognostic value of PET using 18F-FDG in Hodgkin’s disease for posttreatment evalution. J Nucl Med, 2003, 44(8):1225-1231.

相似文献/References:

[1]周玉祥,蓝博文,黄春榆,等.64排螺旋CT冠状动脉血管成像诊断冠状动脉-肺动脉瘘的应用价值[J].国际放射医学核医学杂志,2016,40(1):26.[doi:10.3760/cma.j.issn.1673-4114.2016.01.006]
 Zhou Yuxiang,Lan Bowen,Huang Chunyu,et al.Clinical value of coronary artery-pulmonary artery fistula revealed by 64-slice spiral CT coronary angiography[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):26.[doi:10.3760/cma.j.issn.1673-4114.2016.01.006]
[2]陈超坤,刘亮,傅飞先,等.囊性胸腺瘤和囊性畸胎瘤的影像学特征及鉴别诊断[J].国际放射医学核医学杂志,2016,40(1):31.[doi:10.3760/cma.j.issn.1673-4114.2016.01.007]
 Chen Chaokun,Liu Liang,Fu Feixian,et al.Imaging features and differential diagnosis of cystic thymoma and cystic teratoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):31.[doi:10.3760/cma.j.issn.1673-4114.2016.01.007]
[3]岳进,苏丽萍.全身MRI与PET/CT在淋巴瘤骨髓浸润诊断及预后中的作用[J].国际放射医学核医学杂志,2016,40(1):50.[doi:10.3760/cma.j.issn.1673-4114.2016.01.010]
 Yue Jin,Su Lipin.Function of whole-body MRI and PET/CT in the diagnosis and prognosis of lymphoma with bone marrow infiltration[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):50.[doi:10.3760/cma.j.issn.1673-4114.2016.01.010]
[4]张莹莹,王振光,孔艳.PET/CT显像在肺间质纤维化中的应用进展[J].国际放射医学核医学杂志,2016,40(1):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
 Zhang Yingying,Wang Zhenguang,Kong Yan.Application advancement on PET/CT in pulmonary interstitial fibrosis[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
[5]麦卫平,张永林.能谱CT成像在肺癌诊断中的应用研究进展[J].国际放射医学核医学杂志,2016,40(1):77.[doi:10.3760/cma.j.issn.1673-4114.2016.01.015]
 Mai Weiping,Zhang Yonglin.Research progress of spectral imaging in the diagnosis of lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):77.[doi:10.3760/cma.j.issn.1673-4114.2016.01.015]
[6]周翠屏,廖俊杰,何国华,等.原发性肠系膜巨大淋巴结增生症的MSCT表现与病理对照分析[J].国际放射医学核医学杂志,2016,40(3):175.[doi:10.3760/cma.j.issn.1673-4114.2016.03.003]
 Zhou Cuiping,Liao Junjie,He Guohua,et al.Primary mesenteric Castleman disease:MSCT findings with histopathologic correlation[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):175.[doi:10.3760/cma.j.issn.1673-4114.2016.03.003]
[7]张巧娜,刘汉东.上颌窦上皮-肌上皮癌的CT表现一例[J].国际放射医学核医学杂志,2016,40(3):237.[doi:10.3760/cma.j.issn.1673-4114.2016.03.015]
[8]刘淑蓉,孙凯.低辐射剂量冠状动脉成像的研究进展[J].国际放射医学核医学杂志,2016,40(4):293.[doi:10.3760/cma.j.issn.1673-4114.2016.04.011]
 Liu Shurong,Sun Kai.The advances of low radiation dose coronary computed tomography angiography imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):293.[doi:10.3760/cma.j.issn.1673-4114.2016.04.011]
[9]郑雪,孙凯.双源双能量CT心肌灌注成像的研究进展[J].国际放射医学核医学杂志,2016,40(4):301.[doi:10.3760/cma.j.issn.1673-4114.2016.04.013]
 Zheng Xue,Sun Kai.Progress of dual-energy myocardial perfusion imaging by dual-source computed tomography[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):301.[doi:10.3760/cma.j.issn.1673-4114.2016.04.013]
[10]张巍,杨珂.18f正电子放射性药物生产及使用中医务人员的受照剂量研究[J].国际放射医学核医学杂志,2015,39(5):420.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 016]
 zhang wei,yang ke..the research of radiation dose of 18f-fdg to pet/ct related personnel[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):420.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 016]
[11]史文杰,孟召伟,谭建.基于Deauville标准探讨18F-FDG PET/CT在霍奇金淋巴瘤复发诊断中的应用价值[J].国际放射医学核医学杂志,2016,40(2):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
 Shi Wenjie,Meng Zhaowei,Tan Jian.Value of 18F-FDG PET/CT on diagnosis of Hodgkin lymphoma recurrence using Deauville criterion[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
[12]尤阳,轩昂,张杰,等.淋巴瘤患者大脑静息葡萄糖代谢改变[J].国际放射医学核医学杂志,2016,40(4):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
 You Yang,Xuan Ang,Zhang Jie,et al.Changes in resting-state brain glucose metabolism in patients with lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
[13]王朋,崔邦平,代文莉,等.18F-FDG PET/CT在前列腺癌中的应用进展[J].国际放射医学核医学杂志,2016,40(4):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
 Wang Peng,Cui Bangping,Dai Wenli,et al.Progress in the application of 18F-FDG PET/CT in prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
[14]李菲,黄俊星,张俊.18F-FDG PET/CT在食管癌中的临床应用[J].国际放射医学核医学杂志,2016,40(4):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
 Li Fei,Huang Junxing,Zhang Jun.The clinical application of 18F-FDG PET/CT in esophageal cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
[15]曹登敏,林美福,陈文新,等.继发性骨淋巴瘤的18F-FDG PET/CT影像学表现[J].国际放射医学核医学杂志,2016,40(6):403.[doi:10.3760/cma.j.issn.1673-4114.2016.06.001]
 Cao Dengmin,Lin Meifu,Chen Wenxin,et al.Analysis on 18F-FDG PET/CT imaging characteristics in secondary bone lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):403.[doi:10.3760/cma.j.issn.1673-4114.2016.06.001]
[16]李生栩,唐明灯,林端瑜,等.18F-FDG PET/CT在胸段食管鳞癌淋巴结转移中的诊断价值[J].国际放射医学核医学杂志,2016,40(6):408.[doi:10.3760/cma.j.issn.1673-4114.2016.06.002]
 Li Shengxu,Tang Mingdeng,Lin Duanyu,et al.Value of 18F-FDG PET/CT in detecting metastatic lymph nodes of thoracic esophageal squamous cell carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):408.[doi:10.3760/cma.j.issn.1673-4114.2016.06.002]
[17]张莹莹,王振光,武凤玉,等.特发性肺间质纤维化HRCT病变区与非病变区18F-FDG PET/CT表现分析[J].国际放射医学核医学杂志,2016,40(6):414.[doi:10.3760/cma.j.issn.1673-4114.2016.06.003]
 Zhang Yingying,Wang Zhenguang,Wu Fengyu,et al.18F-FDG PET/CT imaging analysis of regions with abnormal and normal pulmonary parenchyma on high resolution CT in idiopathic pulmonary fibrosis patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):414.[doi:10.3760/cma.j.issn.1673-4114.2016.06.003]
[18]张毓艺,姚稚明.18F-FDG PET/CT对非小细胞肺癌淋巴结分期诊断价值的研究进展[J].国际放射医学核医学杂志,2016,40(6):447.[doi:10.3760/cma.j.issn.1673-4114.2016.06.009]
 Zhang Yuyi,Yao Zhiming.The progress of 18F-FDG PET/CT in the diagnosis of N-staging of non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):447.[doi:10.3760/cma.j.issn.1673-4114.2016.06.009]
[19]郝新忠,武志芳,武萍,等.SAPHO综合征18F-FDG PET/CT显像和临床分析[J].国际放射医学核医学杂志,2015,39(6):447.[doi:10.3760/cma.j.issn.1673-4114.2015.06.003]
 Hao Xinzhong,Wu Zhifang,Wu Ping,et al.18F-FDG PET/CT imaging and clinical features of SAPHO syndrome[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):447.[doi:10.3760/cma.j.issn.1673-4114.2015.06.003]
[20]周文兰,吴湖炳,韩彦江,等.18F-FDG PET/CT对骨骼孤立性高代谢病灶的初步诊断价值[J].国际放射医学核医学杂志,2015,39(1):14.[doi:10.3760/cma.j.issn.1673-4114.2015.01.005]
 Zhou Wenlan,Wu Hubing,Han Yanjiang,et al.Preliminary study of 18F-FDG PET/CT in the diagnosis of solitary hypermetabolic lesion of bone[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):14.[doi:10.3760/cma.j.issn.1673-4114.2015.01.005]

备注/Memo

备注/Memo:
收稿日期:2007-09-10。
通讯作者:赵晋华,E-mail:zjh1963@gmail.com
更新日期/Last Update: 1900-01-01